177 related articles for article (PubMed ID: 37591943)
21. Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth.
Sharma A; Mistriel-Zerbib S; Najar RA; Engal E; Bentata M; Taqatqa N; Dahan S; Cohen K; Jaffe-Herman S; Geminder O; Baker M; Nevo Y; Plaschkes I; Kay G; Drier Y; Berger M; Salton M
PLoS Biol; 2023 Jun; 21(6):e3002175. PubMed ID: 37379322
[TBL] [Abstract][Full Text] [Related]
22. SIX6 is a TAL1-regulated transcription factor in T-ALL and associated with inferior outcome.
Laukkanen S; Oksa L; Nikkilä A; Lahnalampi M; Parikka M; Seki M; Takita J; Degerman S; de Bock CE; Heinäniemi M; Lohi O
Leuk Lymphoma; 2020 Dec; 61(13):3089-3100. PubMed ID: 32835548
[TBL] [Abstract][Full Text] [Related]
23. CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.
Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
[TBL] [Abstract][Full Text] [Related]
24. Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis.
Li Y; Deng C; Hu X; Patel B; Fu X; Qiu Y; Brand M; Zhao K; Huang S
Oncogene; 2012 Nov; 31(48):5007-18. PubMed ID: 22310283
[TBL] [Abstract][Full Text] [Related]
25. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
[TBL] [Abstract][Full Text] [Related]
26. Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
[TBL] [Abstract][Full Text] [Related]
27. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
28. Alteration of CTCF-associated chromatin neighborhood inhibits TAL1-driven oncogenic transcription program and leukemogenesis.
Li Y; Liao Z; Luo H; Benyoucef A; Kang Y; Lai Q; Dovat S; Miller B; Chepelev I; Li Y; Zhao K; Brand M; Huang S
Nucleic Acids Res; 2020 Apr; 48(6):3119-3133. PubMed ID: 32086528
[TBL] [Abstract][Full Text] [Related]
29. Chromatin looping defines expression of TAL1, its flanking genes, and regulation in T-ALL.
Zhou Y; Kurukuti S; Saffrey P; Vukovic M; Michie AM; Strogantsev R; West AG; Vetrie D
Blood; 2013 Dec; 122(26):4199-209. PubMed ID: 24200685
[TBL] [Abstract][Full Text] [Related]
30. Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
Liau WS; Tan SH; Ngoc PCT; Wang CQ; Tergaonkar V; Feng H; Gong Z; Osato M; Look AT; Sanda T
Leukemia; 2017 Aug; 31(8):1798-1807. PubMed ID: 28028313
[TBL] [Abstract][Full Text] [Related]
31. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
32. TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
Cardoso BA; de Almeida SF; Laranjeira AB; Carmo-Fonseca M; Yunes JA; Coffer PJ; Barata JT
Leukemia; 2011 Oct; 25(10):1578-86. PubMed ID: 21647153
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
Mets E; Van der Meulen J; Van Peer G; Boice M; Mestdagh P; Van de Walle I; Lammens T; Goossens S; De Moerloose B; Benoit Y; Van Roy N; Clappier E; Poppe B; Vandesompele J; Wendel HG; Taghon T; Rondou P; Soulier J; Van Vlierberghe P; Speleman F
Leukemia; 2015 Apr; 29(4):798-806. PubMed ID: 25231743
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL.
Ono Y; Fukuhara N; Yoshie O
J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185
[TBL] [Abstract][Full Text] [Related]
35. Correction to: TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
Leukemia; 2024 Mar; 38(3):681-682. PubMed ID: 38272992
[No Abstract] [Full Text] [Related]
36. UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.
Benyoucef A; Palii CG; Wang C; Porter CJ; Chu A; Dai F; Tremblay V; Rakopoulos P; Singh K; Huang S; Pflumio F; Hébert J; Couture JF; Perkins TJ; Ge K; Dilworth FJ; Brand M
Genes Dev; 2016 Mar; 30(5):508-21. PubMed ID: 26944678
[TBL] [Abstract][Full Text] [Related]
37. Cross talk between expression of the human T-cell leukemia virus type 1 Tax transactivator and the oncogenic bHLH transcription factor TAL1.
Terme JM; Wencker M; Favre-Bonvin A; Bex F; Gazzolo L; Duc Dodon M; Jalinot P
J Virol; 2008 Aug; 82(16):7913-22. PubMed ID: 18495761
[TBL] [Abstract][Full Text] [Related]
38. FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2.
Fleskens V; Mokry M; van der Leun AM; Huppelschoten S; Pals CE; Peeters J; Coenen S; Cardoso BA; Barata JT; van Loosdregt J; Coffer PJ
Oncogene; 2016 Aug; 35(31):4141-8. PubMed ID: 26686090
[TBL] [Abstract][Full Text] [Related]
39. TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia.
Sanda T; Leong WZ
Exp Hematol; 2017 Sep; 53():7-15. PubMed ID: 28652130
[TBL] [Abstract][Full Text] [Related]
40. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
